Kreis W - Search Results

1

Predictive initial parameters for response of stage D prostate cancer to treatment with the luteinizing hormone-releasing hormone agonist goserelin.

Kreis W, Ahmann FR, Lesser M, Scott M, Caplan R, Gau T, Vinciguerra V. Kreis W, et al. J Clin Oncol. 1990 May;8(5):870-4. doi: 10.1200/JCO.1990.8.5.870. J Clin Oncol. 1990. PMID: 2139702

2

Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.

Ahmann FR, Citrin DL, deHaan HA, Guinan P, Jordan VC, Kreis W, Scott M, Trump DL. Ahmann FR, et al. Among authors: kreis w. J Clin Oncol. 1987 Jun;5(6):912-7. doi: 10.1200/JCO.1987.5.6.912. J Clin Oncol. 1987. PMID: 2953870 Clinical Trial.

3

Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.

Kreis W, Ahmann FR, Jordan VC, de Haan H, Scott M. Kreis W, et al. Br J Urol. 1988 Oct;62(4):352-4. doi: 10.1111/j.1464-410x.1988.tb04364.x. Br J Urol. 1988. PMID: 2973364

4

Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist.

Kreis W, Budman DR, Delli Bovi P, Vinciguerra V. Kreis W, et al. Onkologie. 1988 Dec;11(6):292-3. doi: 10.1159/000216561. Onkologie. 1988. PMID: 2977219 No abstract available.

5

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.

Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Kreis W, et al. Ann Oncol. 1999 Jan;10(1):33-8. doi: 10.1023/a:1008354600497. Ann Oncol. 1999. PMID: 10076719 Free article. Clinical Trial.

6

Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.

Kreis W, Lesser M, Budman DR, Arlin Z, DeAngelis L, Baskind P, Feldman EJ, Akerman S. Kreis W, et al. Cancer Chemother Pharmacol. 1992;30(2):126-30. doi: 10.1007/BF00686404. Cancer Chemother Pharmacol. 1992. PMID: 1600592

7

Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule.

Budman DR, Kreis W, Behr J, Schulman P, Lichtman S, Allen SL, Weiselberg L, Satterlee WG, Nelson RL, Vinciguerra V. Budman DR, et al. Among authors: kreis w. Invest New Drugs. 1990 Aug;8(3):269-74. doi: 10.1007/BF00171836. Invest New Drugs. 1990. PMID: 2272767 Clinical Trial.

8

Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia.

Kreis W, Rottach C, Budman DR, Chan K, Schulman P, Allen SL, Weiselberg L, Vinciguerra V. Kreis W, et al. Cancer Res. 1988 Oct 1;48(19):5580-4. Cancer Res. 1988. PMID: 3166400

9

Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone.

Ahmann FR, Crawford ED, Kreis W, Levasseur Y. Ahmann FR, et al. Among authors: kreis w. Cancer Res. 1987 Sep 1;47(17):4736-9. Cancer Res. 1987. PMID: 3621171

10

Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors.

Kreis W, Budman DR, Vinciguerra V, Hock K, Baer J, Ingram R, Schacter LP, Fields SZ. Kreis W, et al. Cancer Chemother Pharmacol. 1996;38(4):378-84. doi: 10.1007/s002800050498. Cancer Chemother Pharmacol. 1996. PMID: 8674162 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

185 results

Search Page

Filters